Navigation Links
Oncothyreon announces closing of $15.0 million registered direct financing
Date:8/10/2009

SEATTLE, Aug. 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 million on August 7, 2009. Oncothyreon sold the shares and warrants for $6.5775 per unit (each unit consisting of one share and a warrant to purchase 0.30 shares of common stock). The exercise price of the warrants is $6.5775 per share. The warrants are exercisable at any time on or after the closing and on or prior to the second anniversary of the closing of the transaction on August 7, 2009. Oncothyreon plans to use the proceeds from this financing for general corporate purposes. Rodman Renshaw, LLC, a wholly-owned subsidiary of Rodman Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for Oncothyreon. Boenning Scattergood Inc. acted as financial advisor to Oncothyreon for the offering.

A registration statement relating to these securities (File # 333-149837) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor, shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement, can be obtained at the Securities and Exchange Commission's website, www.sec.gov, from Oncothyreon at its Seattle, Washington address below or Rodman Renshaw LLC by calling 212-356-0549.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)...  Friends, family, healthcare teams and others provide invaluable ... chronic condition affecting the central nervous system. Four MS ... and News , Can Do MS and ... have joined biotechnology company Biogen to recognize ... MS Awareness Month, there are a variety of ways ...
(Date:3/1/2017)... ... March 01, 2017 , ... Morris South ( http://www.morrissouth.com ), ... open house, Southern Tech Fest, April 4-5 in Huntsville, Alabama. The regional machine ... and perform live metal cutting demonstrations throughout the event. More than 20 leading ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... for sensitive, label-free biomolecular interaction analysis, has announced collaborations with Biosys Technologies, ... collaborators expect rapid and effective screening and ranking of inhibitors, thanks to ...
(Date:2/28/2017)... , Australie, 28 février 2017 ... internationale de technologie médicale innovante, et un prestataire ... la santé, des produits et solutions innovantes, et ... nouvelle image de marque sous l,appellation ITL Health ... fait partie du plan de nouvelle image unifiée ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:1/26/2017)... -- Crossmatch, a leading provider of security and identity management ... fraud, waste and abuse in assistance operations around the ... Disaster Relief conference in Panama City ... foreign assistance organizations throughout Latin America ... largely unacknowledged problem in the foreign assistance and disaster ...
Breaking Biology News(10 mins):